7160 related articles for article (PubMed ID: 23342664)
1. [BRAF mutation testing for the choice of melanoma treatment].
Imianitov EN
Arkh Patol; 2012; 74(5):65-71. PubMed ID: 23342664
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
3. Is it good or bad to find a BRAF mutation?
Flaherty KT
J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552
[No Abstract] [Full Text] [Related]
4. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
5. Targeting BRAF in melanoma: biological and clinical challenges.
MandalĂ M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
6. BRAF kinase in melanoma development and progression.
DeLuca AM; Srinivas A; Alani RM
Expert Rev Mol Med; 2008 Feb; 10():e6. PubMed ID: 18279546
[TBL] [Abstract][Full Text] [Related]
7. [Melanoma: from molecular studies to the treatment breakthrough].
Imianitov EN
Arkh Patol; 2013; 75(5):63-72. PubMed ID: 24341237
[TBL] [Abstract][Full Text] [Related]
8. BRAF in melanoma: current strategies and future directions.
Salama AK; Flaherty KT
Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
[TBL] [Abstract][Full Text] [Related]
9. [Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma].
Schadendorf D
J Dtsch Dermatol Ges; 2011 Apr; 9(4):340. PubMed ID: 21439018
[No Abstract] [Full Text] [Related]
10. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
Saroufim M; Habib RH; Gerges R; Saab J; Loya A; Amr SS; Sheikh S; Satti M; Oberkanins C; Khalifeh I
Exp Mol Pathol; 2014 Dec; 97(3):315-20. PubMed ID: 25236573
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
12. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region.
Amanuel B; Grieu F; Kular J; Millward M; Iacopetta B
Pathology; 2012 Jun; 44(4):357-9. PubMed ID: 22614711
[TBL] [Abstract][Full Text] [Related]
13. Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.
Bradish JR; Montironi R; Lopez-Beltran A; Post KM; MacLennan GT; Cheng L
Future Oncol; 2013 Feb; 9(2):245-53. PubMed ID: 23414474
[TBL] [Abstract][Full Text] [Related]
14. BRAF inhibitor activity in V600R metastatic melanoma.
Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
[TBL] [Abstract][Full Text] [Related]
15. BRAF inhibitors: research accelerates in wake of positive findings.
Brower V
J Natl Cancer Inst; 2010 Feb; 102(4):214-5. PubMed ID: 20145213
[No Abstract] [Full Text] [Related]
16. A new standard of care for metastatic melanoma?
Sharma SP
Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638559
[No Abstract] [Full Text] [Related]
17. BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.
Sclafani F; Gullo G; Sheahan K; Crown J
Crit Rev Oncol Hematol; 2013 Jul; 87(1):55-68. PubMed ID: 23246082
[TBL] [Abstract][Full Text] [Related]
18. Oncogenetics of melanoma: basis for molecular diagnostics and therapy.
Held L; Eigentler TK; Meier F; Held M; Röcken M; Garbe C; Bauer J
J Dtsch Dermatol Ges; 2011 Jul; 9(7):510-6. PubMed ID: 21244632
[TBL] [Abstract][Full Text] [Related]
19. Targeting NRAS in melanoma.
Kelleher FC; McArthur GA
Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
[TBL] [Abstract][Full Text] [Related]
20. Absence of V599E BRAF mutations in desmoplastic melanomas.
Davison JM; Rosenbaum E; Barrett TL; Goldenberg D; Hoque MO; Sidransky D; Westra WH
Cancer; 2005 Feb; 103(4):788-92. PubMed ID: 15641040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]